Related Experiment Video
Updated: Apr 18, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
[A case of thymic cancer effectively treated by weekly paclitaxel combined with carboplatin]
Rie Kondo1, Satoshi Watanabe, Daisuke Ishikawa
1Dept. of Internal Medicine II, Niigata University Medical and Dental Hospital.
Abstract:
A 65-year-old woman with left chest pain, back pain, and palpitation that had persisted for 2 months was referred to our hospital. Computed tomography of her chest showed an anterior mediastinal tumor with mediastinal lymphadenopathy, left pleural effusion, and pericardial effusion. Endobronchial ultrasound-guided transbronchial needle aspiration of the subcarinal lymphadenopathy was performed. The pathological findings and other examinations such as bone scintigraphy suggested advanced thymic cancer (stage IV b according to the Masaoka classification of thymic epithelial tumors). The patient was treated with combination chemotherapy of carboplatin(area under the curve [AUC]=6, 656 mg/body, day 1) and weekly paclitaxel (70 mg/m², 100 mg/body, days 1, 8, and 15). After 4 cycles of chemotherapy, a partial response was achieved and the pericardial effusion disappeared. The patient did not experience any severe toxicity, except for grade 1 nausea, grade 2 anemia, and grade 2 alopecia. Weekly paclitaxel combined with carboplatin appears to be a useful regimen with minimal toxicity for advanced thymic cancer.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Tumor Immunotherapy
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies

